Short answer
Tango Therapeutics, Inc. (TNGX) filed an 8-K current report with the SEC on May 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers). Q1 2026 results covered quarter ended March 31, 2026.
Tango Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results covered quarter ended March 31, 2026
- Press release issued May 13, 2026 and furnished as Exhibit 99.1
- Investors should review Exhibit 99.1 for operating results and financial-condition details
Item 5.02 · Departure/Election of Directors or Officers
- Alexis Borisy resigned as Lead Independent Director and Compensation Committee chair effective May 13, 2026
- Kanishka Pothula resigned as director and Nominating and Corporate Governance Committee member effective May 13, 2026
- Both departures cited no disagreements with company operations, practices, or policies
- Sung Lee became Lead Independent Director and Compensation Committee chair, consolidating key oversight responsibilities
- Board committees reconstituted with Compensation Committee at three members and NCG Committee at three members
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tango Therapeutics, Inc. 8-K filings
Get the next TNGX 8-K as it lands
Follow TNGX for push alerts, or ask the research agent what this filing means.